Compare O'will Corp. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 18.66%
- Healthy long term growth as Operating profit has grown by an annual rate 26.02%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.41
2
With ROCE of 17.51%, it has a very attractive valuation with a 1.03 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,606 Million (Micro Cap)
6.00
NA
0.00%
0.69
14.86%
1.12
Revenue and Profits:
Net Sales:
11,396 Million
(Quarterly Results - Jun 2026)
Net Profit:
426 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.04%
0%
5.04%
6 Months
-3.18%
0%
-3.18%
1 Year
-68.12%
0%
-68.12%
2 Years
-56.55%
0%
-56.55%
3 Years
-44.86%
0%
-44.86%
4 Years
-31.13%
0%
-31.13%
5 Years
-32.41%
0%
-32.41%
O'will Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.79%
EBIT Growth (5y)
26.02%
EBIT to Interest (avg)
65.98
Debt to EBITDA (avg)
1.06
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
3.87
Tax Ratio
31.21%
Dividend Payout Ratio
24.96%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.45%
ROE (avg)
15.05%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.04
EV to EBIT
5.88
EV to EBITDA
5.32
EV to Capital Employed
1.03
EV to Sales
0.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.51%
ROE (Latest)
17.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
11,395.70
9,563.20
19.16%
Operating Profit (PBDIT) excl Other Income
699.40
-25.30
2,864.43%
Interest
26.20
22.70
15.42%
Exceptional Items
0.00
-60.00
100.00%
Consolidate Net Profit
426.20
-58.70
826.06%
Operating Profit Margin (Excl OI)
58.20%
-6.90%
6.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 19.16% vs -10.95% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 826.06% vs -125.33% in Mar 2026
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
41,909.20
39,156.00
7.03%
Operating Profit (PBDIT) excl Other Income
1,500.50
1,255.80
19.49%
Interest
72.70
44.90
61.92%
Exceptional Items
-87.20
0.00
Consolidate Net Profit
802.50
916.40
-12.43%
Operating Profit Margin (Excl OI)
32.70%
29.70%
0.30%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 7.03% vs 23.23% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -12.43% vs 31.67% in Mar 2025
About O'will Corp. 
O'will Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






